Definium Therapeutics (DFTX) Current Assets (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Current Assets data on file, last reported at $380.6 million in Q1 2026.

• Current Assets for Q1 2026 came in at $380.6 million, up 71.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $380.6 million (up 71.66% YoY), and the FY2025 annual result was $419.3 million, up 48.9% from the prior year.
• Current Assets slipped to $380.6 million in Q1 2026 per DFTX's latest filing, from $419.3 million in the prior quarter.
• Over five years, Current Assets peaked at $419.3 million in Q4 2025 and troughed at $103.9 million in Q4 2023.
• A 5-year average of $207.2 million and a median of $189.1 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets retreated 28.88% in 2023, then soared 171.12% in 2024.
• A 5-year view of Current Assets shows it stood at $146.1 million in 2022, then dropped by 28.88% to $103.9 million in 2023, then soared by 171.12% to $281.6 million in 2024, then jumped by 48.9% to $419.3 million in 2025, then declined by 9.24% to $380.6 million in 2026.
• Business Quant data shows DFTX's Current Assets at $380.6 million in Q1 2026, $419.3 million in Q4 2025, and $215.8 million in Q3 2025.